CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $46,525 | -35.0% | 1,025 | -19.6% | 0.00% | -33.3% |
| Q2 2023 | $71,579 | +201.4% | 1,275 | +142.9% | 0.01% | +200.0% |
| Q1 2023 | $23,746 | +11.3% | 525 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $21,341 | -37.2% | 525 | -0.4% | 0.00% | -33.3% |
| Q3 2022 | $34,000 | +6.2% | 527 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $32,000 | -8.6% | 527 | -5.9% | 0.00% | +50.0% |
| Q1 2022 | $35,000 | -14.6% | 560 | +4.7% | 0.00% | -33.3% |
| Q4 2021 | $41,000 | -64.3% | 535 | -47.8% | 0.00% | -62.5% |
| Q3 2021 | $115,000 | -29.9% | 1,025 | +1.3% | 0.01% | -27.3% |
| Q2 2021 | $164,000 | +33.3% | 1,012 | 0.0% | 0.01% | +22.2% |
| Q1 2021 | $123,000 | +1437.5% | 1,012 | +1846.2% | 0.01% | +800.0% |
| Q4 2020 | $8,000 | – | 52 | +2500.0% | 0.00% | – |
| Q3 2020 | $0 | – | 2 | 0.0% | 0.00% | – |
| Q2 2020 | $0 | – | 2 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |